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1. Introduction
   Zinc-α-2-glycoprotein (ZAG) is a 40-kilodalton (kDa) 
single-chain polypeptide with many important functions, 
such as fertilization and lipid mobilization[1]. ZAG is 
structurally similar to major histocompatibility complex 
class I molecules and considered to be an adipokine[2-4]. 
This soluble protein has been discovered to enhance 
lipolysis and influence other physiological processes[5]. 
Furthermore, ZAG levels have been correlated with a variety 
of diseases, such as atherosclerosis[6], type II diabetes and 
a number of carcinomas[7,8]. ZAG is normally produced by 
the epithelial cells in several tissues, including the liver, 
adipose tissues, sweat glands, breasts and gastrointestinal 
tract[9]. It is found in various bodily fluids such as plasma, 
semen, sweat, milk and cerebrospinal fluid[10]. The plasma 
concentration of ZAG is affected by several factors, including 
body weight and health status. 
   Due to its stimulation of lipolysis, elevated ZAG levels may 
lead to weight loss and further complications especially for 
patients with acquired immunodeficiency syndrome (AIDS)
[4]. Prolonged usage of combined antiretroviral therapy 
(cART) in AIDS patients is associated with toxicities that 
may limit their success. Among these toxicities is the 
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appearance of lipodystrophy syndrome. This includes a 
series of body morphological changes including peripheral 
fat atrophy and truncal fat accumulation[11].
   To the best of our knowledge, this is the first study in the 
region to investigate the levels of ZAG among AIDS patients. 
2. Materials and methods
 
2.1. Participants
   The sample group (n=80) comprised of 45 (56%) male 
patients and 35 (44%) female patients with AIDS who were 
receiving cART at Sultan Qaboos University Hospital (SQUH), 
Muscat, Oman. The age range of the patients was 18 to 70 
years, with the majority (60, 75%) of them aged between 20 to 
60 years (mean依SD=35.75依3.75 years). Information concerning 
patients’ weights was obtained using the SQU hospital’s 
internal information system. The control group consisted of 
80 healthy blood donors, 34 (43%) females and 46 (57%) males, 
who were visiting the SQUH Blood Bank from various regions 
in Oman. The age ranges of the healthy individuals were 
between 18 to 55 years, with the majority (56, 70%) of them 
between 20 to 40 years (mean依SD=25.75依3.75 years). 
   This study was approved by the Medical Research 
Committee and the Ethics Committee of the College of 
Medicine & Health Sciences of Sultan Qaboos University. 
2.2. Measurement of ZAG levels
   The serum analysis for determining the ZAG levels 
was carried out using a competitive enzyme-linked 
immunosorbent assay (ELISA) (Abnova GmbH Corp., 
Heidelberg, Germany), which utilized anti-ZAG antibodies 
to indirectly detect the amount of ZAG proteins in the sera 
samples. The assays were performed according to the 
manufacturer instructions. 
2.3. Data analysis
   The Statistical Package for Social Sciences (SPSS version 
20) was used for data processing and analysis. Data were 
described using mean, standard deviation, median as 
well as the 95% confidence interval (CI) of the mean. Chi-
squared was used to test the significance of the associations 
between the ZAG levels and the variables of age and gender. 
The presence of a significant correlation was assessed using 
Spearman’s rank correlation coefficient test. Significance of 
the obtained results was judged at the 5% level relying on 
exact P value.
3. Results
3.1. ZAG levels in healthy individuals and AIDS patients
   The distribution of ZAG levels in the serum samples of 
AIDS patients and the healthy individuals is demonstrated 
in Figure 1. A significant difference in ZAG distribution was 
clearly shown between the AIDS patients and the healthy 
people, with a 96.2% level of confidence (P=0.033). 
   A total of 6 (7.5%) of the AIDS patients were found to have 
ZAG levels within the normal range (20 to 35 ng/mL), compared 
with 10 (12.5%) of the healthy individuals. Nineteen (23.75%) 
of the AIDS patients were found to have low ZAG levels 
(<20 ng/mL), which is more than two times higher than the 
finding among the healthy people 7 (8.75%). No significant 
differences were detected between the AIDS patients and the 
healthy people with regards to the high levels of ZAG (>35 ng/
mL).
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Figure 1. The distribution of ZAG level among AIDS patients and control group. 
Low ZAG levels: <20 ng/mL; Normal level: 20-35 ng/mL; High ZAG level: >35 ng/mL. 
3.2. The relationship between patients’ gender and ZAG levels
   The distribution of ZAG levels among AIDS patients and the 
healthy people (controls) in relation to gender is displayed 
in Figure 2. The frequency (21%) of AIDS female patients with 
low ZAG levels was found to be higher than females in the 
healthy group. This is in contrast to findings for the normal 
ZAG levels and high range categories; a higher percentage 
of females in the healthy group were found to have normal 
to high ZAG levels compared with that of the AIDS female 
patients group. Additionally, the subgroup of AIDS male 
patients showed similar, results. With the exception of the 
high ZAG level category, the frequency of AIDS male patients, 
with high ZAG levels, was higher than the males in the 
healthy control group.
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Figure 2. A histogram showing the frequency of ZAG levels by gender among 
Omani AIDS patients and the healthy people (control group). 
A histogram showing the frequency of ZAG levels by gender among Omani 
AIDS patients and the healthy people (control group). Line showed the median 
distribution for each cut off values. Low ZAG levels: <20 ng/mL; Normal level: 20-35 
ng/mL; High ZAG level: >35 ng/mL.
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3.3. The relationship between patients’ age and ZAG levels
   The distribution of ZAG levels among the AIDS patients 
and healthy people in relation to age is shown in Figure 3. 
Among the age group of 20 to 40 years, although a higher 
frequency (24%) of AIDS patients demonstrated low levels of 
ZAG in comparison to the healthy people, this finding was 
not significant. However, among the age group 40 to 60 years, 
AIDS patients showed a higher frequency compared with 
the healthy group, in both the low and high ZAG categories 
(Figure 3).
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Figure 3. A histogram showing the frequency of ZAG levels by age among Omani 
AIDS patients and healthy individuals (Control). 
Low ZAG levels: <20 ng/mL; Normal level: 20-35 ng/mL; High ZAG level: >35 ng/mL.
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   The weight of the AIDS patients was observed over a period 
of one year, and it has been found that AIDS patients had 
high ZAG levels along with an observed decreased in weight, 
(data not shown). However, about 10% of the patients also had 
high ZAG level with increase in weight.  
4. Discussion
   ZAG is a novel adipokine having a major role in normal 
health and in chronic diseases[12]. ZAG is known to stimulate 
lipolysis in murine epididymal adipocytes through the 
stimulation of adenylate cyclase in a guanosine triphosphate 
(GTP)-dependent process via binding through the h3-
adrenoceptor[13,14]. It is involved preferentially in the 
depletion of fatty acids from the adipose tissues, and 
accordingly named as lipid-mobilizing factor[15].
   This study indicated the majority of both the AIDS patients 
and the healthy individuals were found to have high ZAG 
levels. However, relatively lower ZAG levels were found 
among the AIDS patients receiving cART. 
   An alternate conceivable relationship exists between ZAG 
levels and patients with AIDS who are experiencing weight 
reduction. Such a correlation was illustrated by Ceperuelo-
Mallafré et al. in 2012, when they demonstrated that ZAG 
levels were lower in AIDS patients on antiviral medications 
than in sound uninfected individuals. The findings of this 
study are in agreement with those reported by Ceperuelo-
Mallafré et al. that AIDS patients receiving cART showed 
lower ZAG levels than the control group[4]. 
  The stimulation of lipolysis is one of the ZAG protein’s 
major functions. cART for patients with AIDS usually increase 
lipolysis by decreasing the triglyceride accumulation, 
lipogenesis and the articulation of the adipose markers; 
in addition, they also increase lipolysis by stimulating fat 
catabolism[16]. As per the part that ZAG proteins play in 
lipolysis, it might be anticipated that cART has an alternate 
conceivable mechanism causing lipolysis: an increment in 
ZAG amalgamation and secretion. This may contribute to 
explaining the high ZAG levels found in this study among the 
majority of AIDS patients receiving cART. Apart from cART, 
there are different possibilities to explain the high ZAG levels 
in the AIDS patients receiving cART. The HIV infection itself 
may increase ZAG levels[4]; an alternate probability is the 
known association between ZAG levels and cancer, as cancer 
is one of the common complications of AIDS[17]. In fact AIDS 
is known to involve inflammatory responses that may result 
from a combined effect of the cART, the increase of lipolytic 
activity and the metabolic disturbances.
   The highest levels of ZAG in both AIDS patients and the 
healthy individuals appeared among the age group 20-40 
years, which could be illustrated by its cooperation with 
high metabolic rates[18]. In the age group 40-60 years, the 
AIDS patients showed higher ZAG levels than the control 
group. This could be due to several factors, such as AIDS-
related complications, antiviral drugs or the infection by HIV. 
Therefore, this study indicates the need for measurements of 
ZAG levels not only among AIDS patients but possibly among 
other patients especially prior to blood transfusions for 
patients who are clinically underweight.
   Gender seems to play no role in the change of ZAG level. 
It was observed that the distribution of ZAG levels in AIDS 
patients is not influenced by the gender of the patient, as 
ZAG levels among the male and female subgroups were 
proportionally similar. 
   Previous studies have suggested that ZAG level was 
correlated with weight loss in healthy uninfected patients[19]. 
Our results however, showed that, 16 (20%) AIDS patients 
have high levels ZAG levels, which are significantly (P>0.031) 
associated with weight loss. Interestingly, 10% of the patients 
with high ZAG levels showed increase in their weight. High 
ZAG levels in these patients may precede the process of 
developing AIDS-related complications such as cancer. 
Additionally, this study showed that age might influence the 
plasma levels of ZAG.
   ZAG levels are high among Omani AIDS patients on cART 
and this necessitates the measurement of ZAG levels on 
routine basis, as it is associated with weight loss.
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Comments 
Background
   This is a good study and the authors investigated the levels 
of ZAG among Omani AIDS patients receiving cART. This is a 
first study to correlate the stimulation of lipolysis with the 
level of ZAG with weight loss especially for patients with 
AIDS. The results demonstrated ZAG levels are high among 
Omani AIDS patients on cART and this necessitates the 
measurement of ZAG on routine basis, as it is associated with 
weight loss. 
Research frontiers
   The study was carried out to investigate the correlation 
of ZAG and its elevation “if any” associated with patients 
suffering from HIV infection. Among the different clinical 
complications that HIV and/or AIDS patients experience are 
toxicities in which this study exploited is the appearance 
of lipodystrophy syndrome. This includes a series of body 
morphological changes including peripheral fat atrophy and 
truncal fat accumulation.
    The main cutting edge in the field of research in this 
paper is the first report to correlate the stimulation of 
lipolysis with the level of ZAG with weight loss especially for 
patients with AIDS.
Related reports
   Authors have taken note of earlier studies of other 
disesese related to ZAG level [Fantuzzi G. Adipose tissue, 
adipokines, and inflammation (2005); Delort L et al. Zinc-
α2-glycoprotein: a proliferative factor for breast cancer? In 
vitro study and molecular mechanisms (2013)]. 
Innovations and breakthroughs
   This paper is an excellent pilot study from which a 
considerable work can be headed in the future, which may 
play a vital role in considering blood transfusion with those 
patients with clinical underweight. 
  
Applications
   The present investigation revealed that measuring the ZAG 
level could be one of the future parameter(s) to be considered 
in blood transfusion. It is important to study and investigate 
this further in detail to evaluate the clinical correlation of 
the elevated ZAG level and weight loss. Therefore, this pilot 
study and the consideration of any subsequent research of 
ZAG and weight loss may act as a future blood transfusion 
guideline.
Peer review
   This is an adequate pilot study in which the authors 
have investigated the level of ZAG and its correlation with 
HIV/AIDS patients in parallel with health individuals. The 
experimental design and results were well demonstrated. It 
has very good scope to further continue this work with more 
advanced tools to prove that the measurement of ZAG level 
may be one of the blood transfusion necessary parameters 
for those who are clinically underweight. 
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